Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed
consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive)
- Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal
tolerated dose documented in the patient medical record) for 90 days prior to screening
Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant
or is of child-bearing potential and not using an adequate contraceptive method (adequate
contraceptive measures as required by local regulation or practice) - Any condition, which
in the investigator's opinion might jeopardise subject's safety or compliance with the
protocol - Treatment with any medication for the indication of diabetes or obesity other
than stated in the inclusion criteria in a period of 90 days before screening. An exception
is short-term insulin treatment for acute illness for a total of equal to or below 14 days
- History of pancreatitis (acute or chronic) - Screening calcitonin equal to or above 50
ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary
Thyroid Carcinoma - Renal impairment defined as eGFR (electronic case report form) below 60
mL/min/1.73 m^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) -
Subjects presently classified as being in New York Heart Association Class IV - Planned
coronary, carotid or peripheral artery revascularisation on the day of screening -
Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of
malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and
in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more
than 14 consecutive days or on a frequent basis) known to affect weight or glucose
metabolism (e.g. orlistat, thyroid hormones, corticosteroids)